Blocking the LLT1-CD161 signaling pathway in lung cancer [15], prostate cancer [18], and diffuse glioma [19] can inhibit the activity of NK cells and may become a breakthrough agent in immunotherapy. Here, CLEC2D is linked to Familial prostate cancer.